COMPANY ANNOUNCEMENT - No. 20-2023 -
MAY NOT BE PUBLISHED, DISTRIBUTED OR DELIVERED FULLY OR IN PART, DIRECTLY OR INDIRECTLY, IN OR TO
BIRKERØD,
Background for the Offering and use of proceeds
1) Promote new application areas and continue reimbursement processes in
Push the application of suPARnostic® within guiding treatment in sepsis patients to previous, existing, and new hospital customers, building upon the results from the study of the
2) Obtain marketing approval and initiate expansion to the US
Continue collaboration with Sobi on submitting a 510k application (marketing authorization) for emergency department use of suPARnostic® before licensed roll-out. Additionally, pursue opportunities within the clinical lab segment, where internal lab-developed test applications are being explored.
3) Approach the health clinics and longevity segment
Develop new marketing approach and sales channels for the use of suPARnostic® in the longevity field. Establish connections to KOL’s within the area. This is a segment new to
Summary of the terms of the Offering
On
- The subscription price is
DKK 4.5 per share. -
The offer is carried out as a rights issue, with a minimum offering of 1,624,283 shares (the “Minimum Offer”) and a maximum offering of 3,350,507 shares (the “Maximum Offer”), each with a nominal value of
DKK 1 . The gross proceeds from a fully subscribed Minimum Offering isDKK 7,309,274 and gross proceeds from a fully subscribed Maximum Offering will amount toDKK 15,077,282 . -
Shares in the Offering are offered with pre-emptive rights for the Company's Existing Shareholders. Existing Shareholders will be allotted one (1) subscription right for each (1) existing share that the shareholder owns at the time of allotment. One (1) subscription right gives the holder right to subscribe for one (1) new share in
ViroGates .
Timetable for the Offering
- 28 November –
11 December 2023 : Trading in Subscription Rights - 30 November –
13 December 2023 : Subscription Period 15 December 2023 before 12.00 CET: Announcement of outcome of the Offering19 December 2023 : Payment for shares subscribed for and allocated without use of Subscription Rights19 December 2023 : Capital increase registered with theDanish Business Authority 21 December 2023 : First day of trading for shares subscribed in the Offering in the permanent ISIN22 December 2023 : Shares subscribed in the offering under temporary ISIN merged into permanent ISIN
Subscription undertakings
The company has received binding subscription undertakings to subscribe for a total of 1,624,283 shares, corresponding to gross proceeds of DKK 7,309,274.
The following existing shareholders have made binding subscription undertakings using pre-emptive rights in the Offering:
| Undertaking, number of shares | Undertaking, amount | Share-holdings before Offering | Affiliation with the Company |
794,672 | 23.85% | Shareholder | ||
340,909 | 10.23% | Shareholder | ||
| 340,876 | 10.23% | Shareholder and non- exec. board member |
The following representatives from the Board and management have made binding subscription undertakings using pre-emptive rights in the Offering:
| Undertaking, number of shares | Undertaking, amount | Share-holdings before Offering | Affiliation with the Company |
90,000 | 4.54% | CSO | ||
44,551 | 1.34% | CEO | ||
8,017 | 0.24% | VP Sales & Marketing | ||
5,258 | 0.16% | CoB |
Detailed terms for the Offering and investment brochure
Complete terms and conditions for the Offering and other information about the Company is available in company announcement no. 17-2023 of
Issuing agent and Settlement Agent in the Offering
Holmens Kanal 2-12
1092 København K
CVR no. 61 12 62 28
Important notice
This announcement is a briefing to the Company's shareholders and is not an offer or solicitation to subscribe for or purchase subscription rights or shares in the Company. There is no public offering of shares outside Denmark. Persons outside
This announcement contains certain forward-looking statements, including statements about the Company's activities. Such forward-looking statements are based on information, assumptions and assessments that the Company finds reasonable. These forward-looking statements include known and unknown risks, uncertainties and other significant factors that may cause the Company's actual results, development or performance or the industry's results to differ materially from future results, developments or performance expressed or implied in connection therewith. If one or more of these risks or uncertainties are triggered, or if an underlying assumption proves to be incorrect, the Company's actual financial position or operating results may deviate significantly from what is described.
Potential investors, companies and advisers should be aware that investments in companies whose shares are admitted to trading on the Nasdaq First North Growth Market Denmark may carry a higher risk than investments in listed companies on a regulated market, as defined in EU legislation. Instead, they are subject to a less comprehensive set of rules and legislation adapted to smaller growth companies. The companies on Nasdaq First North Growth Market often have a shorter operational history and are thus more sensitive to external and internal influences and fluctuations. Likewise, liquidity, and thus marketability, in shares admitted to trading on Nasdaq First North Growth Market Denmark may be more limited than in investments in shares listed on a regulated market.
The announcement can be found at https://www.virogates.com/announcements/.
For further information, please contact:
CEO,
Tel. (+45) 2226 1355, email: jk@virogates.com
Certified Advisor:
Västra Hamnen Corporate Finance
Per Lönn
Tel. (+46) 40 200 250, email: ca@vhcorp.se
About
The company was founded in 2000. Headquartered in
About suPAR and suPARnostic®
suPAR is the biomarker detected by ViroGates’ suPARnostic® products and is a protein in plasma, measurable in every human being. suPAR is considered a general risk status biomarker indicating disease presence, disease severity and progression, organ damage and mortality risk across disease areas such as cardiovascular diseases, kidney diseases, type 2 diabetes, cancer, etc. Strong scientific evidence from more than 900 clinical trials and studies show that the higher the level of suPAR, the worse the prognosis for the patient.
The suPARnostic® products can be used to support healthcare professionals in making clinical decisions. The increasing demands on health systems globally and tightening healthcare budgets necessitate efficiency improvements and innovative solutions in hospitals. The use of suPAR in triage in emergency departments can identify patients in low risk of disease progression (supports discharge) and high risk patients that can benefit from early treatment to lower the risk of disease progression. suPARnostic® TurbiLatex is currently available on Roche Diagnostics’ cobas® instruments,
Disclosure regulation
Prospects about the future reflect
Contacts
Jakob Knudsen , CEO, +45 2226 1355, jk@virogates.com
Attachments
- 20231130 -
ViroGates Company ann. 20.pdf
© Ritzau Denmark, source